title: [Leihong granule intervened in-stent restenosis after endovascular therapy for lower extremity arterial occlusive diseases: a clinical observation].
abstract: OBJECTIVE
  To observe the intervention effect of Leihong Granule (LG) in in-stent restenosis (ISR) after endovascular therapy for lower extremity arterial occlusive diseases (LEAOD).
  
  
  METHODS
  Recruited 80 LEAOD patients who successfully underwent endovascular therapy (balloon dilation and stent implantation) were randomly assigned to two groups, the control group and the LG group, 40 in each group. Patients in the control group received basic treatment, while those in the LG group additionally took LG for 3 months. Plasma levels of IL-10, IL-18, CRP, and the intima-media thickness (IMT) of lower extremity artery were observed in the two groups between and after treatment. The rate of stent patency, ABI, intermittent claudication, rest pain, and the incidence of amputation the two groups were recorded and observed in the two groups.
  
  
  RESULTS
  In the control group, serum levels of IL-10, IL-18, CRP, and IMT were significantly higher one month after surgery than before surgery (P < 0.05). There was no significant difference in serum levels of IL-10, IL-18, CRP, or IMT between the two groups before surgery (P > 0.05). These indices were obviously lower in the LG group than in the control group after surgery (P < 0.05). Compared with the control group, the incidence rates of intermittent claudication and the rest pain at 6 months and 12 months after surgery significantly decreased (P < 0.05). The stent patency rate at 6 months and 12 months after surgery, and ABI were significantly higher than those of the control group (P < 0.05). There was no statistical difference in the amputation rate between the two groups (P > 0.05).
  
  
  CONCLUSIONS
  LG might effectively improve ischemic symptoms of affected limbs possibly through lowering the ISR rate after endovascular therapy for LEAOD through preventing immunosuppressive actions.
authors.forename: Bing
authors.initials: B
authors.lastname: Han
authors.forename: Chang-Qing
authors.initials: CQ
authors.lastname: Ge
authors.forename: Li-Pu
authors.initials: LP
authors.lastname: Wang
authors.forename: Su-Fei
authors.initials: SF
authors.lastname: Zhang
authors.forename: Heng-Zhou
authors.initials: HZ
authors.lastname: Li
authors.forename: Hong-Guang
authors.initials: HG
authors.lastname: Zhang
authors.forename: Chen-Guang
authors.initials: CG
authors.lastname: Zhou
authors.forename: Guo-Hui
authors.initials: GH
authors.lastname: Ji
authors.forename: Zheng
authors.initials: Z
authors.lastname: Yang
authors.forename: Liang
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001157:Arterial Occlusive Diseases / Q000628:therapy; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006083:Graft Occlusion, Vascular / Q000628:therapy*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D020382:Interleukin-18 / Q000097:blood; D035002:Lower Extremity / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D015607:Stents; D016896:Treatment Outcome
chemical_list: D004365:Drugs, Chinese Herbal; D020382:Interleukin-18; D016753:Interleukin-10